CTTN

FAK, or Focal Adhesion Kinase, is a crucial protein involved in various cellular processes within the human body. It plays a significant role in cell adhesion, migration, proliferation, and survival. FAK acts as a signaling molecule, transmitting signals from the extracellular matrix to the cell's interior, thereby regulating cell behavior. It is particularly important in processes like wound healing, tissue development, and cancer progression. FAK's dysregulation has been linked to several diseases, making it an attractive target for pharmaceutical interventions. Understanding the role of FAK in the human body is essential for developing therapeutic strategies to modulate its activity and potentially treat various disorders. FAK, also known as Focal Adhesion Kinase, is activated by receptor tyrosine kinases (RTK), intracellular pH changes (H+), integrins, G protein-coupled receptors (GPCR), and cytokine receptors. It increases cell motility by influencing signal transduction mediated by ARP2/3, RHO guanine nucleotide exchange factor (RHOGEF), talin or cortactin, and SRC or PI3K. Research has found that FAK is overexpressed in various types of tumors, including ovarian cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, prostate cancer, and head and neck cancer, and is associated with poor prognosis in many cancers. Inhibiting or degrading FAK can inhibit the proliferation, migration, and invasion of tumor cells. Moreover, researchers have found that inhibiting the FAK signaling pathway can effectively reverse various chemotherapy and targeted therapy failures caused by tumor resistance, and can enhance the response and efficacy of immunotherapy for solid tumors. However, the development of FAK inhibitors has not been smooth. Although FAK inhibitors have shown some anti-tumor activity in some tumors, no significant improvement in disease treatment has been observed in the research of various companies. Therefore, companies that initially engaged in the development of FAK inhibitors chose to give up halfway. Among them, Pfizer Inc. transferred defactinib to Verastem, and Boehringer Ingelheim GmbH (BI) transferred IN10018 to Inxmed (Nanjing) Co., Ltd. Overall, the target FAK shows promising potential in the pharmaceutical industry, with multiple companies, indications, drug types, and countries/locations involved in its development. Further research and development efforts are needed to fully explore the therapeutic benefits and commercial potential of targeting FAK. The mechanism of action of FAK inhibitorsFAK inhibitors are a type of drug that target and inhibit the activity of focal adhesion kinase (FAK). FAK is a protein that plays a crucial role in cell signaling and is involved in various cellular processes such as cell adhesion, migration, and proliferation. FAK inhibitors work by blocking the enzymatic activity of FAK, thereby preventing its downstream signaling pathways. From a biomedical perspective, FAK inhibitors have gained significant attention in cancer research. Abnormal activation of FAK has been implicated in tumor growth, invasion, and metastasis. By inhibiting FAK, these inhibitors can potentially disrupt the signaling pathways that promote cancer progression. Therefore, FAK inhibitors are being investigated as potential therapeutic agents for various types of cancer. In addition to cancer, FAK inhibitors may also have implications in other diseases and conditions where FAK signaling is dysregulated. For example, they could potentially be used to modulate fibrosis, inflammation, and angiogenesis. It is important to note that FAK inhibitors are still under development and further research is needed to determine their safety and efficacy in different clinical settings. Catalog of FAK InhibitorsThe currently marketed FAK inhibitors include: ConteltinibDefactinibGSK-2256098IfebemtinibAMP-945APG-2449HP-530SBI-3663DNX-5000GSK215For more information, please click on the image below. What is the purpose of using FAK inhibitors?FAK inhibitors are under investigation for indications that include multiple cancer such as Non-small cell lung cancer; Pancreatic cancer; Pancreatic cancer; Pancreatic cancer: Meningioma and other solid tumors. For more information, please click on the image below to log in and search. How can I get the most recent advancements in FAK inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of FAK inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

HDAC6, or histone deacetylase 6, is an enzyme that plays a crucial role in the regulation of gene expression and protein function in the human body. It is primarily involved in the removal of acetyl groups from proteins, thereby influencing their activity and stability. HDAC6 has been found to be particularly important in various cellular processes, including cell migration, protein degradation, and immune response. Dysregulation of HDAC6 has been associated with several diseases, including cancer, neurodegenerative disorders, and autoimmune conditions. Therefore, understanding the role of HDAC6 in the human body is essential for the development of targeted therapies and potential treatments for these diseases. HDAC6 is the largest member of the HDAC family, consisting of 1215 amino acids. It is mainly composed of a nuclear export signal (NES), two functionally independent HDAC catalytic domains (CD1 and CD2, located at the N-terminus and the center, respectively), and a zinc finger ubiquitin-binding domain (at the C-terminus). The zinc finger ubiquitin-binding domain can be used to bind ubiquitin proteasomes to clear misfolded proteins. The nuclear export signal (NES) allows HDAC6 to be transported to the cytoplasm and target non-histone substrates in the cytoplasm, such as α-tubulin, tau protein, cortactin, heat shock protein (HSP90), and peroxidase. HDAC6 plays an important physiological role in cellular pathways, and its abnormal activity directly leads to various diseases, such as cancer, neurodegenerative diseases, immune disorders, etc. The latest research shows that HDAC6 is a potential target for a variety of rare diseases, such as Rett syndrome (RTT), inherited retinal diseases (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT), etc. The classic HDAC inhibitor structure is mainly divided into three parts: ① the cap group that recognizes the protein surface and blocks other substrates from entering the active pocket, ② the linker, and ③ the functional group (Zn-binding Group, ZBG) that binds to the active center Zn2+. The affinity and selectivity of HDAC inhibitors with different HDAC subtypes are mainly determined by the interaction mode between these three parts and the catalytic site, so the activity and selectivity can be optimized by adjusting these three parts. The analysis of target HDAC6 in the pharmaceutical industry reveals a competitive landscape with multiple companies actively involved in R&D. Bristol Myers Squibb Co., Chong Kun Dang Pharmaceutical Corp., and Regenacy Pharmaceuticals LLC are among the companies growing fastest under this target. The indications for drugs targeting HDAC6 cover a wide range of therapeutic areas. Small molecule drugs and unknown drug types are progressing rapidly, indicating intense competition in the development of innovative drugs. The European Union, the United States, South Korea, and Canada are the countries/locations developing fastest under this target, with China also showing progress. Overall, the future development of target HDAC6 holds promise in addressing various diseases and improving patient outcomes. The mechanism of action of HDAC6 inhibitorsFrom a biomedical perspective, HDAC6 inhibitors refer to a class of drugs that specifically target and inhibit the activity of the enzyme called histone deacetylase 6 (HDAC6). HDAC6 is a member of the histone deacetylase family, which plays a crucial role in regulating gene expression and protein function by removing acetyl groups from histone proteins and non-histone proteins. By inhibiting HDAC6, these inhibitors can modulate the acetylation status of proteins, leading to various cellular effects. HDAC6 inhibitors have shown potential therapeutic benefits in the field of biomedicine, particularly in the treatment of cancer and neurodegenerative diseases. They have been found to promote cell cycle arrest, induce cell death, inhibit angiogenesis, and enhance immune responses. In cancer treatment, HDAC6 inhibitors can interfere with the growth and survival of cancer cells by altering the acetylation status of proteins involved in cell proliferation, apoptosis, and DNA repair. Additionally, they can sensitize cancer cells to other anti-cancer therapies, such as chemotherapy and radiation therapy. In the context of neurodegenerative diseases, HDAC6 inhibitors have demonstrated neuroprotective effects and the ability to enhance the clearance of toxic protein aggregates, such as tau and alpha-synuclein, which are implicated in diseases like Alzheimer's and Parkinson's. This makes HDAC6 inhibitors a potential therapeutic strategy for slowing down disease progression and preserving neuronal function. Overall, HDAC6 inhibitors are a promising class of drugs with diverse biomedical applications, and ongoing research aims to further explore their therapeutic potential in various disease conditions. Catalog of HDAC6 InhibitorsThe currently marketed HDAC6 inhibitors include: CitarinostatCKD-506RocilinostatJBI-802CKD-504CKD-510CS-3003JIN-002TYA-11631[18F]EKZ-001For more information, please click on the image below. What is the purpose of using HDAC6 inhibitors?Inhibitors of HDAC6 have demonstrated potential advantages in biomedical applications, notably in addressing malignancies and disorders related to neurodegeneration. For more information, please click on the image below to log in and search. How can I get the most recent advancements in HDAC6 inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of HDAC6 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!